Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Mounjaro – which competes in the market with Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) – was 8% better than ...

Demand for drugs, including weight-loss injections, is sending people to dangerous places to get their medicine. But spotting ...

On a recent weekday evening, Ashly Richards helped her 13-year-old son, Case, with homework. He did math problems and some ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

In May, the Danish pharma said CEO Lars Fruergaard Jørgensen would step down, following a turn in the obesity market. While Novo was the star of the emerging weight loss and diabetes market through ...

Novo Nordisk A/S (NYSE:NVO) came up during the show in the context of trade discussions between the US and Europe and ...

Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...